Search 

Intract Pharma Limited is an oral drug delivery licensing and product development company offering a range of proprietary formulation technologies to deliver novel and optimised therapeutics targeted to patient needs. The company is a spin-out of University College London, and is centred around over 15 years of research and innovation from the laboratory of Professor Abdul Basit. Intract's range of formulation technologies includes Phloral™ for colon targeted delivery, and ProRelease™, a versatile microparticulate delivery system.

Isogenica is at the forefront of synthetic biology, pursuing a mission to provide the fastest, most efficient engine for therapeutic antibody discovery. Isogenica is developing LlamdA™ (single domain VHH) and Alexandria™ (human Fab) therapeutic antibodies based on its proprietary fully synthetic antibody libraries and leveraging its CIS Display and Colibra™ technologies to accelerate the discovery and development process.

Our team combines drug discovery specialists with physicists, chemists and computer scientists committed to use cutting-edge technologies to make a difference to people’s lives.

Kuano's approach is to combine state-of-the-art simulation and AI to add quantum detail to structure based drug discovery. Our unique fusion of drug hunting and technology expertise allows us to illuminate new areas of chemical space enabling the design of next generation medicines.

Providing patients with a new way to benefit from Naltrexone

We transform promising life science ideas into medical breakthroughs that change patients’ lives.

Making life science life changing: We transform promising life science ideas into medical breakthroughs that change patients’ lives.

We specialise in early-stage translation – advancing lab-based scientific discoveries to a point at which they can be developed into the next generation of diagnostics, treatments and cures.

Lifescience Industry magazine is a collaboration between regional, national and international life science partners including BioPartner UK.

It includes the latest news and developments from the life science industry, with editorial covering the complete health technology spectrum, as well as funding, trade and collaboration opportunities. 
Currently circulated twice a year to over 40,000 named individuals, it is consistently distributed at key industry events around the world and is available online.

BioPartner members can submit articles free of charge, and receive 15% off all advertising packages.

MedCity is the life sciences cluster organisation for London and the greater south east of England, set up in 2014 by the Mayor of London and the region’s three Academic Health Science Centres. They are funded by the Greater London Authority and Research England, and as a not-for-profit are able to act as a neutral and independent convener across industry, academia and the public sector.

London and the greater south east is home to a rich life sciences cluster, with more than 3,400 life sciences companies, four of the world’s top ten universities, 19 of the top 20 global pharmaceutical companies and world class research centres including The Francis Crick Institute, Harwell Oxford and The Sanger Institute.

MedCity's ambition is for their region to be the unequivocal place of choice for world-leading health and life sciences innovation, R&D, manufacture and commercialisation.

Medherant is developing a pipeline of products for pain and neurology indications, based on our next-generation TEPI-Patch® transdermal drug technology. Our first product – Ibuprofen TEPI Patch – entered the clinic in 2018.

Key advantages of the TEPI Patch® technology over current technologies are the high payload and very efficient release of drug.  This enables lower potency drugs to be formulated as a patch and provides the opportunity to increase the dose of drugs already administered via a patch whilst also minimising the residual drug after use.  

The TEPI Patch® also provides a better experience for the user as it does not leave a residue around the patch – referred to as ‘cold flow’ – and has excellent adhesion whilst still being easy and painless to remove. No organic solvents are involved in this drug-in-adhesive system.

As well as developing our own products, Medherant offers pharma companies rapid feasibility studies using our proprietary high throughput permeation study system to develop transdermal formulations of their drugs of interest.

MediWales is the life science network and representative body for Wales.
An independent, not-for-profit organisation that is owned by its members, MediWales provides advice, support, business opportunities and promotes collaborations for the life science and health technology community in Wales.

MediWales delivers an extensive events programme, including the UK HealthTech conference and the MediWales Innovation Awards and produces a number of publications including UK Lifescience Industry magazine, the Annual Directory and Review, and case study magazine LifeStories. MediWales promotes and supports its members in Wales, across the UK and internationally. 

Mironid is an innovative drug discovery company that develops proprietary drug candidate molecules by modulating the activity of key cell signaling proteins.